<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259138</url>
  </required_header>
  <id_info>
    <org_study_id>RP1706</org_study_id>
    <secondary_id>2019-002485-12</secondary_id>
    <nct_id>NCT04259138</nct_id>
  </id_info>
  <brief_title>Determination of the Optimal Treatment Target in Ulcerative Colitis</brief_title>
  <acronym>VERDICT</acronym>
  <official_title>VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alimentiv Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alimentiv Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disease activity and response to therapy in ulcerative colitis (UC) can be assessed by a&#xD;
      range of endpoints including symptoms, endoscopic mucosal activity, histological disease&#xD;
      activity, and biomarkers. This study aims to determine the optimal treatment target, which is&#xD;
      a research priority for the management of UC both to inform clinical practice and to help&#xD;
      inform regulatory endpoints and targets for drug development.&#xD;
&#xD;
      Participants with active UC will be randomized in a 2:3:5 ratio to 1 of 3 groups, each with a&#xD;
      different treatment target. Treatment targets will be defined as:&#xD;
&#xD;
        -  Group 1: corticosteroid-free symptomatic remission&#xD;
&#xD;
        -  Group 2: corticosteroid-free endoscopic + symptomatic remission&#xD;
&#xD;
        -  Group 3: corticosteroid-free histological + endoscopic + symptomatic remission&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this study, participants with active UC will be randomized in a 2:3:5 ratio to 1 of 3 treatment target groups. Participants will be assigned a treatment algorithm based on their existing UC treatment at time of entry. Treatment algorithms may include the use of vedolizumab. A key premise is that vedolizumab has a favorable safety profile and can be used to treat subjects who are in symptomatic remission but who have not attained endoscopic or histopathologic remission.&#xD;
Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Investigators will be trained on the treatment algorithms and target groups. Study participants will be blinded to target group assignment, whereas investigators will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Time to UC-related Complication Between Treatment Target Groups 1 and 3</measure>
    <time_frame>From date of treatment target achievement until date of first UC-related complication until end of study (Week 96), whichever came first</time_frame>
    <description>Time to UC-related complication starting when a participant reaches their assigned treatment target, compared between treatment target groups 1 and 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Time to UC-related Complication Compared Between Treatment Target Groups 1 and 2.</measure>
    <time_frame>From date of treatment target achievement until date of first UC-related complication until end of study (Week 96), whichever came first</time_frame>
    <description>Time to UC-related complication starting when a participant reaches their assigned treatment target, compared between treatment target groups 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Time to UC-related Complication Compared Between Treatment Target Groups 2 and 3.</measure>
    <time_frame>From date of treatment target achievement until date of first UC-related complication until end of study (Week 96), whichever came first</time_frame>
    <description>Time to UC-related complication starting when a participant reaches their assigned treatment target, compared between treatment target groups 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Time to UC-related Complication Compared Between Treatment Target Groups (fast responder sub-group)</measure>
    <time_frame>From date of treatment target achievement until date of first UC-related complication until end of study (Week 96), whichever came first</time_frame>
    <description>Time to UC-related complication (as in the primary outcome and secondary outcomes 3 and 4) in the subgroup of subjects who exclusively reach their assigned target and not a higher target by Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Time to Achieve Treatment Target</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Time taken to achieve the respective targets among the randomized groups. Time will be censored for subjects who do not achieve their assigned target by Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Calprotectin Levels</measure>
    <time_frame>Baseline, weeks 8, 16, 32, 48, and 96.</time_frame>
    <description>Change in fecal calprotectin levels from baseline to Weeks 8, 16, 32, 48, and 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein Concentration</measure>
    <time_frame>Baseline, weeks 8, 16, 32, 48, 64, 80, and 96</time_frame>
    <description>Change in C-Reactive Protein concentration from baseline to Weeks 8, 16, 32, 48, 64, 80, and 96</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Symptomatic remission</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment target defined as achievement of corticosteroid-free symptomatic remission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic and endoscopic remission</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic, endoscopic and histological remission</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission plus histological remission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Treatment Algorithm A</intervention_name>
    <description>Participants who are treatment-na√Øve at randomization will follow treatment algorithm A. Participants, upon entry into the study, will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (with optional oral corticosteroid in combination) will be initiated.&#xD;
Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.</description>
    <arm_group_label>Symptomatic and endoscopic remission</arm_group_label>
    <arm_group_label>Symptomatic remission</arm_group_label>
    <arm_group_label>Symptomatic, endoscopic and histological remission</arm_group_label>
    <other_name>vedolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Treatment Algorithm B</intervention_name>
    <description>Participants who are taking non-biologic UC therapies at randomization will follow treatment algorithm B.&#xD;
Participants will change to intravenous vedolizumab therapy.&#xD;
Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.</description>
    <arm_group_label>Symptomatic and endoscopic remission</arm_group_label>
    <arm_group_label>Symptomatic remission</arm_group_label>
    <arm_group_label>Symptomatic, endoscopic and histological remission</arm_group_label>
    <other_name>vedolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Treatment Algorithm C</intervention_name>
    <description>Participants who are taking anti-TNF, tofacitinib or ustekinumab therapy at randomization will follow treatment algorithm C.&#xD;
Participants will change to intravenous vedolizumab therapy.&#xD;
Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.</description>
    <arm_group_label>Symptomatic and endoscopic remission</arm_group_label>
    <arm_group_label>Symptomatic remission</arm_group_label>
    <arm_group_label>Symptomatic, endoscopic and histological remission</arm_group_label>
    <other_name>vedolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of UC confirmed by clinical, endoscopic, and histological evidence prior to&#xD;
             screening as per standard criteria&#xD;
&#xD;
          -  Moderately to severely active UC with a Mayo rectal bleeding subscore ‚â• 1 and a Mayo&#xD;
             endoscopic subscore (MES) ‚â• 2, with minimum disease extent of 15 cm and objective&#xD;
             evidence of inflammation that can be visualized using central endoscopic imaging&#xD;
             system&#xD;
&#xD;
          -  Ability of subject to participate fully in all aspects of this clinical trial&#xD;
&#xD;
          -  Written informed consent must be obtained and documented&#xD;
&#xD;
          -  Agree not to participate in an investigational trial for the duration of the trial&#xD;
             (observation trials without investigational product may be permitted at the discretion&#xD;
             of the investigator)&#xD;
&#xD;
          -  Willing to perform a standard of care tuberculosis (TB) test and hepatitis B and C&#xD;
             test prior to starting any biologic drug during the study, unless negative results&#xD;
             available from within 12 months prior&#xD;
&#xD;
          -  A male subject who is nonsterilized* and sexually active with a female partner of&#xD;
             childbearing potential* agrees to use adequate contraception* from signing of informed&#xD;
             consent throughout the duration of the study and for 18 weeks after last dose&#xD;
&#xD;
          -  A female subject of childbearing potential who is sexually active with a&#xD;
             nonsterilized* male partner agrees to use routinely adequate contraception* from&#xD;
             signing of informed consent throughout the duration of the study and for 18 weeks&#xD;
             after last dose&#xD;
&#xD;
          -  Up to date with colorectal carcinoma surveillance according to local standards and&#xD;
             guidelines. If a subject is not up to date at screening, a standard of care&#xD;
             surveillance assessment may be performed during the screening period.&#xD;
&#xD;
          -  Subjects who are not responding to their existing treatment for UC&#xD;
             (Netherlands-specific criterion).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have historically failed (i.e., had an inadequate response with, lost&#xD;
             response to, or were intolerant to) 2 or more compounds or classes of advanced&#xD;
             therapeutic options (biologics or small molecules; e.g., anti-TNFs, ustekinumab, or&#xD;
             tofacitinib) for the treatment of their UC&#xD;
&#xD;
          -  Current or previous treatment with vedolizumab, ertrolizumab, or natalizumab&#xD;
&#xD;
          -  Topical therapy (corticosteroid or 5-aminosalicylate [5-ASA]) use within 2 weeks prior&#xD;
             to screening endoscopy&#xD;
&#xD;
          -  Change to oral corticosteroid dosing within 2 weeks prior to screening&#xD;
&#xD;
          -  Known diagnosis of CD, indeterminate colitis, ischemic colitis, radiation colitis,&#xD;
             diverticular disease associated with colitis, or microscopic colitis&#xD;
&#xD;
          -  Short gut syndrome&#xD;
&#xD;
          -  Positive stool culture for or active Clostridioides difficile infection (as&#xD;
             demonstrated by positive toxin and/or antigen)&#xD;
&#xD;
          -  Known hepatitis B or C infection. If a negative test result is available in the 12&#xD;
             months prior to randomization, retesting is not required&#xD;
&#xD;
          -  Known active or latent TB. If a negative test results is available in the 12 months&#xD;
             prior to randomization, confirmatory testing is not required&#xD;
&#xD;
          -  Received any investigational drug within 30 days prior to randomization/target&#xD;
             assignment&#xD;
&#xD;
          -  Serious underlying disease other than UC that in the opinion of the investigator may&#xD;
             interfere with the subject's ability to participate fully in the study or would&#xD;
             compromise subject safety (such as history of malignancies, major neurological&#xD;
             disorders, or any unstable or uncontrolled medical disorder)&#xD;
&#xD;
          -  History of alcohol or drug abuse that in the opinion of the investigator may interfere&#xD;
             with the subject's ability to comply with the study procedures&#xD;
&#xD;
          -  The subject has active cerebral/meningeal disease, signs, symptoms, or any history of&#xD;
             progressive multifocal leukoencephalopathy (PML) prior to randomization&#xD;
&#xD;
          -  Hypersensitivity to any excipient of vedolizumab .&#xD;
&#xD;
          -  Active severe infection such as sepsis, cytomegalovirus, listeriosis, or opportunistic&#xD;
             infection.&#xD;
&#xD;
          -  History of HIV or positive test at screening (Italy-specific criterion).&#xD;
&#xD;
          -  Any other contraindication(s)to vedolizumab (Italy-specific criterion).&#xD;
&#xD;
          -  If female, the subject is pregnant or lactating or intending to become pregnant&#xD;
             before, during, or within 18 weeks after the last dose; or intending to donate ova&#xD;
             during such time period.&#xD;
&#xD;
          -  If male, the subject intends to donate sperm during the course of this study or for 18&#xD;
             weeks after the last dose.&#xD;
&#xD;
          -  Vaccination with a live or live-attenuated vaccine within 4 weeks prior to&#xD;
             randomization, or planned vaccination during conduct of the study, except vaccination&#xD;
             for coronavirus disease of 2019 (COVID 19).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vipul Jairath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alimentiv Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharine Nelson</last_name>
    <phone>+1 858-768-2260</phone>
    <email>verdictcsm@alimentiv.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huron Gastroenterology Associates - Center for Digestive Care</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Shah</last_name>
    </contact>
    <investigator>
      <last_name>Najm Soofi, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mt Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sari Feldman</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Frederic Colombel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asheville Gastroenterology Associates, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Roberts</last_name>
    </contact>
    <investigator>
      <last_name>William Harlan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health (Carolinas HealthCare)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Macko</last_name>
    </contact>
    <investigator>
      <last_name>John Hanson, MD, AGAF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerp</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ils Van De Schoot</last_name>
    </contact>
    <investigator>
      <last_name>Peter Bossuyt, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <state>East Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lien Van Den Bossche</last_name>
    </contact>
    <investigator>
      <last_name>Triana Lobaton Ortega, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Thijs</last_name>
    </contact>
    <investigator>
      <last_name>Marc Ferrante, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nima Hamidi</last_name>
    </contact>
    <investigator>
      <last_name>Remo Panaccione, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GIRI (GI Research Institute)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Chris Colman</last_name>
    </contact>
    <investigator>
      <last_name>Brian Bressler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrie GI Associates Inc.</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colayna Harris-Mailloux</last_name>
    </contact>
    <investigator>
      <last_name>Rima Petroniene, MD, PhD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Campus</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Prins</last_name>
    </contact>
    <investigator>
      <last_name>Melanie Beaton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LHSC - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindi Wessman</last_name>
    </contact>
    <investigator>
      <last_name>Terry Ponich, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ABP Research Services Corp.</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6L 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ananya Sahni</last_name>
    </contact>
    <investigator>
      <last_name>Naveen Arya, BSc, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taunton Surgical Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 0C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alana Carter</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Immune and Digestive Health Institute (TIDHI)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajani Jeyakumar</last_name>
    </contact>
    <investigator>
      <last_name>Mark Silverberg, MD, PhD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Etienne Hopital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabila Boukhadra</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Roblin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besan√ßon - H√¥pital Jean Minjoz</name>
      <address>
        <city>Besan√ßon</city>
        <state>Bourgogne-Franche-Comte</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Vaurie</last_name>
    </contact>
    <investigator>
      <last_name>Lucine Vuitton, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <state>Hauts-de-France</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Cunysse</last_name>
    </contact>
    <investigator>
      <last_name>Benjamin Pariente, (Prof) MD, MBBS, PhD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hopital Haut Leveque - Groupe Hospitalier Sud</name>
      <address>
        <city>PESSAC cedex</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cavillon Elodie</last_name>
    </contact>
    <investigator>
      <last_name>David Laharie, (Prof) MS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier - Hopital Saint Eloi</name>
      <address>
        <city>MONTPELLIER cedex 05</city>
        <state>Occitanie</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perrine Rocher</last_name>
    </contact>
    <investigator>
      <last_name>Romain Altwegg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hopital l'Archet II</name>
      <address>
        <city>NICE Cedex 03</city>
        <state>Provence-Alpes-Cote d'Azur</state>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joris Condat</last_name>
    </contact>
    <investigator>
      <last_name>J√©rome Filippi, MS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC - Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolien Van Den Broeck</last_name>
    </contact>
    <investigator>
      <last_name>Geert D'Haens, MD, PHD, AGAF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lucas</last_name>
    </contact>
    <investigator>
      <last_name>Simon Travis, MRCP, Dphil, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull &amp; East Yorkshire NHS Trust</name>
      <address>
        <city>Hull</city>
        <state>Yorkshire</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Myers</last_name>
    </contact>
    <investigator>
      <last_name>Shaji Sebastian, MD, MRCP, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

